AVITA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AVITA (AVITA).
Retinoic acid receptor agonist; binds to nuclear retinoic acid receptors (RARs) to regulate gene expression, promoting epithelial cell turnover and differentiation.
| Metabolism | Hepatic oxidation via CYP450 enzymes; glucuronidation. |
| Excretion | Renal (biliary/fecal negligible): unchanged drug 70-80% within 48h. |
| Half-life | Terminal half-life 1.5-2.5h; clinically q4h dosing achieves steady state within 24h. |
| Protein binding | 80-90% bound to serum albumin (binding protein). |
| Volume of Distribution | 0.5-1.0 L/kg; indicates distribution into total body water. |
| Bioavailability | Oral: 70-80% (first-pass metabolism reduces it). |
| Onset of Action | Oral: 30-60 min; IV: immediate. |
| Duration of Action | Oral/IV: 4-6h; clinical effect correlates with serum levels >0.5 mcg/mL. |
Apply topically once daily at bedtime. Use a pea-sized amount for the entire face. Avoid eyes, mouth, and mucous membranes.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. Systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for hepatic impairment. Systemic absorption is minimal. |
| Pediatric use | Not recommended for use in children under 12 years of age due to insufficient data on safety and efficacy. |
| Geriatric use | No specific dose adjustment recommended. Use with caution in elderly patients due to increased risk of skin irritation and dryness. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AVITA (AVITA).
| Breastfeeding | Contraindicated during breastfeeding. Retinoids are excreted in human milk; milk/plasma ratio not established. Potential for serious adverse effects in nursing infants. |
| Teratogenic Risk | First trimester: high risk of major fetal malformations including CNS, cardiovascular, and craniofacial defects (retinoid embryopathy). Second and third trimesters: risk of spontaneous abortion, preterm birth, and fetal growth restriction. Contraindicated in pregnancy. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to tretinoin or any component","Pregnancy (relative; consider risk/benefit)","Eczema","Sunburn or skin conditions causing irritation"]
| Precautions | ["Avoid excessive sun exposure; use sunscreen","Pregnancy Category C; avoid if pregnant or planning pregnancy","Local skin reactions: erythema, peeling, dryness, burning","May increase sensitivity to wind and cold weather"] |
| Food/Dietary | No known food interactions. Avoid excessive alcohol intake which may increase skin sensitivity. |
| Clinical Pearls |
Loading safety data…
| Pregnancy test before initiation, monthly pregnancy tests during therapy, and 1 month after discontinuation. Fetal ultrasound if inadvertent exposure occurs. |
| Fertility Effects | No direct negative impact on fertility in males or females; however, due to teratogenicity, strict contraceptive measures are required in women of childbearing potential. |
| AVITA (tretinoin) is a topical retinoid used for acne vulgaris and photoaging. Start with low concentration (0.025%) to minimize irritation; apply pea-sized amount at night. Avoid concurrent use of other topical irritants (e.g., benzoyl peroxide, salicylic acid) initially. Use sunscreen daily due to photosensitivity. Contraindicated in pregnancy (Category C); discontinue if pregnancy occurs. |
| Patient Advice | Apply a thin layer once daily at bedtime to clean, dry skin. · May cause redness, peeling, and burning initially; use moisturizer as needed. · Avoid sun exposure and use SPF 30+ sunscreen daily. · Do not apply to broken skin, eczema, or sunburned areas. · Do not use if pregnant, planning pregnancy, or breastfeeding. · Results may take 8-12 weeks for acne improvement. |